Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides

Intuitive Venture PartnersDecember 26, 20232023, entera bio

Aeluma Appoints Seasoned Semiconductor Industry Executive Craig Ensley to its Board of Directors

Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective technologies for

Intuitive Venture PartnersDecember 21, 2023aeluma, 2023

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform

Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides

Intuitive Venture PartnersNovember 30, 2023entera bio, 2023

Aeluma Wins Second Navy Award

Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective technologies for

Intuitive Venture PartnersNovember 28, 2023Aeluma, 2023

Aeluma Awarded Navy Funding to Develop Photonics Reliability Methodologies for Defense and Aerospace Applications

Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective technologies for

Intuitive Venture PartnersNovember 2, 2023aeluma, 2023

Aeluma Hub Leader USC Named Recipient of CHIPS Act Microelectronics Commons Award

Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective technologies for

Intuitive Venture PartnersSeptember 26, 2023aeluma, 2023

Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. (NASDAQ: OPK,

Intuitive Venture PartnersSeptember 12, 2023entera bio, 2023

Guerilla RF Announces First Production PO For Satcom Market Securing Stronger Second Half 2023

Guerrilla RF, Inc. (OTCQX: GUER), a leading provider of state-of-the-art radio frequency and microwave

Lori TullmanSeptember 8, 2023guerrilla, 2023

Augmedix Announces Expanding Coverage in Behavioral Health Field for Acute and Ambulatory Care Settings

Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical

Intuitive Venture PartnersSeptember 6, 2023Augmedix, 2023

Serve Robotics Inc. Announces Go-Public Transaction and $30 Million Financing to Support Scaling of Robotic Delivery

Serve Robotics, Inc. (“the Company” or “Serve”), the leading autonomous sidewalk delivery company, today a

Intuitive Venture PartnersAugust 25, 2023Serve Robotics, 2023

Aeluma, Inc. Closes $6 Million Oversubscribed Common Stock Only Private Placement

Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective sensor technologies

Intuitive Venture PartnersMay 12, 20232023, Aeluma

Lumicell™ DVS Pivotal Trial Results Published in NEJM Evidence and to Be Presented at ASBrS Assess Safety and Effectiveness of System for Identifying Residual Breast Cancer During Lumpectomy

Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer

Intuitive Venture PartnersMay 8, 2023Lumicell, 2023

Ostendo Technologies, Inc. and Veea Inc. to Merge

Ostendo Technologies, Inc., and Veea Inc. today announced the signing of a letter of intent to combine Ostendo’s

Intuitive Venture PartnersMarch 6, 2023Ostendo, 2023

Guerrilla RF Completes Final Closing of $9.2 Million Private Placement Equity Financing

Guerrilla RF, Inc. (OTCQX: GUER), a leading provider of state-of-the-art RF and microwave communications

Intuitive Venture PartnersMarch 6, 2023Guerilla, 2023

Aeluma Achieves Photodetector Performance Milestone with its Large-Diameter Wafer Manufacturing Platform

Aeluma, Inc. (the "Company") (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective

Intuitive Venture PartnersMarch 6, 2023aeluma, 2023

Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones:

Intuitive Venture PartnersJuly 18, 20222022, entera bio

Aeluma, Inc. Names Former Head of Business Development for Continental's LiDAR Product Line, Thomas Laux, as Vice President of Business Development

Aeluma, Inc., announced today that it has named Thomas Laux as Vice President of Business Development.

Intuitive Venture PartnersMay 3, 2022aeluma, 2022

Virsec Secures $100 Million Show of Force Investment as it Redefines How Software is Secured

Virsec Systems, Inc. secures $100 million “show of force” investment as it redefines how software is secured.

Intuitive Venture PartnersJuly 14, 20212021, virsec

Aeluma, Inc. Raises $8 Million and Completes Reverse Merger

Aeluma, Inc. raises $8 million and completes reverse merger.

Intuitive Venture PartnersJuly 7, 20212021, aeluma

Entera Bio Announces Positive Topline EB613 Phase 2 Biomarker Data

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announces positive topline EB613 phase 2 biomarker data

Intuitive Venture PartnersApril 6, 2021entera bio, 2021